Autologous Progenitor Cells Delivery in Renovascular Disease

肾血管疾病中的自体祖细胞输送

• 批准号: 7462813
• 负责人: Lilach O Lerman
• 金额: $ 18.89万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7462813
• 关键词: Address; Adjuvant Therapy; Angiography; Angioplasty; Architecture; Atherosclerosis; Autologous; Balloon Angioplasty; Blood Vessels; Cardiovascular system; Cells; Chronic; Chronic Kidney Failure; Data; Deterioration; Development; Diagnostic; Disease; End stage renal failure; Endothelium; Epithelial; Epithelial Cells; Etiology; Experimental Models; Family suidae; Functional disorder; Healed; Image; Imaging Techniques; In Situ; In Vitro; Individual; Injury; Intervention; Kidney; Light; Measures; Medicine; Microcirculation; Modeling; Morbidity - disease rate; Morphology; Organ; Outcome; Oxidation-Reduction; Pathogenesis; Patients; Perfusion; Physiological; Play; Population; Procedures; Public Health; Recovery; Renal Artery Stenosis; Renal function; Renovascular Hypertension; Role; Simulate; Stem cells; Structure; Sus scrofa; System; Techniques; Testing; Therapeutic; Tissues; Tubular formation; Urination; Vascular Diseases; Western World; Work; Wound Healing; X-Ray Computed Tomography; cell injury; design; healing; hemodynamics; improved; improved functioning; in vivo; injured; kidney vascular structure; mortality; neovascularization; novel; novel strategies; novel therapeutics; peripheral blood; repaired; response; success

DESCRIPTION (provided by applicant): The impact of vascular disease on morbidity and mortality is on the rise in the Western world. Atherosclerotic renal artery stenosis (ARAS), a common etiology of chronic kidney disease and renovascular hypertension, amplifies deterioration of renal function compared to RAS alone. Furthermore, by amplifying endothelial and epithelial cell injury and impairing vascular cellular repair mechanisms, atherosclerosis exacerbates irreversible damage in the stenotic kidney and blunts its ability to recover following revascularization. Adequate strategies to improve these grave outcomes are yet to be identified, but are in dire need. The working hypothesis underlying this proposal is that replenishment of autologous progenitor cells (APC) would restore renal cellular integrity and improve the function, structure, and recovery prospects of the ARAS kidney. This hypothesis will be tested in a novel pig model of unilateral ARAS that we have developed and characterized, using unique imaging approaches that we have refined to study single-kidney function and structure. APC will be isolated from peripheral blood, expanded in vitro, and then administered into the stenotic kidney in conjunction with renal angiography or percutaneous transluminal renal angioplasty (PTRA), to study longitudinally their effects on single-kidney hemodynamics, function, response to challenge, and recovery potential. The in vivo studies will be correlated with in vitro characterization of the in situ 3D architecture of the renal microcirculation, renal redox status, and morphology in APC-treated and -untreated kidneys. Our new preliminary data show that APC improved the function and structure of the ischemic kidney, demonstrating the feasibility of this approach to confer renal protection. These studies will pursue 2 specific aims. Specific Aim 1 will test the hypothesis that replenishment of APC would improve the basal function and structure of the ARAS kidney. Specific Aim 2 will test the hypothesis that enhancing cellular repair by intra-renal delivery of APC, immediately after PTRA and during the same procedure, would improve the response of the ARAS kidney to intervention and restore its recovery potential. The proposed studies may greatly advance our understanding of the pathogenesis of renal injury in ARAS, and establish a novel, clinically feasible therapeutic strategy. Furthermore, they may assist in development of strategies to identify predictors of renal viability and improve the success of treatment. Thus, these studies may contribute towards management of patients with atherosclerosis and renovascular disease. PUBLIC HEALTH RELEVANCE: There is a pressing need to define the mechanisms by which atherosclerotic renovascular disease damages the kidney, and develop strategies to protect it. The proposed studies may advance our understanding of the pathogenesis of renal injury, and will determine the ability of autologous progenitor cells (which can be isolated from the individual's peripheral blood, and help repair renal vascular and other cells) to improve renal outcomes in this disease. These studies are likely to shed important light into and have a substantial ramification for designing and directing diagnostic and therapeutic measures for management of patients with renovascular disease.

描述（由申请人提供）：在西方世界，血管疾病对发病率和死亡率的影响正在上升。动脉粥样硬化性肾动脉狭窄（ARAS）是慢性肾脏疾病和肾血管性高血压的常见病因，与单独的RAS相比，它会加剧肾功能的恶化。此外，动脉粥样硬化通过放大内皮细胞和上皮细胞损伤以及损害血管细胞修复机制，加剧了狭窄肾的不可逆损伤，并削弱了其在血运重建后的恢复能力。改善这些严重后果的适当战略尚未确定，但迫切需要。该建议的工作假设是，补充自体祖细胞（APC）可以恢复肾细胞的完整性，改善ARAS肾脏的功能、结构和恢复前景。这一假设将在我们开发和表征的新型单侧ARAS猪模型中得到验证，该模型使用我们改进的独特成像方法来研究单肾功能和结构。APC将从外周血中分离出来，体外扩增，然后结合肾血管造影或经皮腔内肾血管成形术（PTRA）注入狭窄肾，纵向研究其对单肾血流动力学、功能、应激反应和恢复潜力的影响。体内研究将与体外对apc处理和未处理肾脏的原位肾脏微循环3D结构、肾脏氧化还原状态和形态的表征相关。我们新的初步数据显示，APC改善了缺血肾脏的功能和结构，证明了这种方法赋予肾脏保护的可行性。这些研究将追求两个具体目标。特异性目的1将验证补充APC会改善ARAS肾的基础功能和结构的假设。特异性目标2将验证这样一个假设：在PTRA后立即在同一过程中通过肾内递送APC来增强细胞修复，将改善ARAS肾脏对干预的反应并恢复其恢复潜力。本研究将有助于我们进一步了解ARAS肾损伤的发病机制，并建立一种新的、临床可行的治疗策略。此外，它们可能有助于制定策略，以确定肾脏生存能力的预测因素，并提高治疗的成功率。因此，这些研究可能有助于动脉粥样硬化和肾血管疾病患者的管理。公共卫生相关性：迫切需要明确动脉粥样硬化性肾血管疾病损害肾脏的机制，并制定保护策略。拟议的研究可能会促进我们对肾损伤发病机制的理解，并将确定自体祖细胞（可以从个体外周血中分离出来，并帮助修复肾血管和其他细胞）改善该疾病肾脏预后的能力。这些研究可能对设计和指导肾血管性疾病患者的诊断和治疗措施有重要意义。